Evaluation of the Efficacies of Liraglutide and Glargine in Type 2 Diabetes Patients with Malignant Tumors Treated with Glucocorticoids

作者全名："Pu, D. L.; Jiang, J.; Song, C.; Xi, J. Z.; Wu, Q."

作者地址："[Pu, D. L.] Peoples Hosp Yubei Dist Chongqing City, Dept Endocrinol, Chongqing 401120, Peoples R China; [Jiang, J.] Chongqing Univ, Sch Med, Canc Hosp, Dept Endocrinol & Nephrol, Chongqing 400044, Peoples R China; [Song, C.] Chongqing Med Univ, Childrens Hosp, Endocrinol Dept, Chongqing 400015, Peoples R China; [Xi, J. Z.; Wu, Q.] Chongqing Med Univ, Peoples Hosp Dazu, Dazu Hosp, Dept Endocrinol, Chongqing 402360, Peoples R China"

通信作者："Wu, Q (通讯作者)，Chongqing Med Univ, Peoples Hosp Dazu, Dazu Hosp, Dept Endocrinol, Chongqing 402360, Peoples R China."

来源：INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES

ESI学科分类：PHARMACOLOGY & TOXICOLOGY

WOS号：WOS:000789148100024

JCR分区：Q4

影响因子：0.5

年份：2022

卷号：84

期号：　

开始页：168

结束页：177

文献类型：Article

关键词：Malignant tumor; liraglutide; glargine; glucocorticoid; type 2 diabetes mellitus

摘要："To explore the efficacies of liraglutide and glargine in type 2 diabetes patients with malignant tumors treated with glucocorticoids. Overall, 120 patients were recruited, 60 patients were divided into the glargine group (chemotherapy with glucocorticoids and hypoglycemic therapy including glargine) and 60 patients were divided into the liraglutide group (chemotherapy with glucocorticoids and hypoglycemic therapy including liraglutide). Fasting plasma glucose, 2 h postprandial plasma glucose, glycosylated hemoglobin, body mass index, systolic blood pressure, diastolic blood pressure, C peptide, insulin resistance index, insulin secretion index, total cholesterol, triglyceride, high-density lipoprotein, low-density lipoprotein, Karnofsky performance status score, rehospitalization rate, average hospitalization days and adverse reactions before and after intervention were compared between the two groups. After treatment, total cholesterol, high-density lipoprotein, C peptide, systolic blood pressure, diastolic blood pressure and homeostatic model assessment of insulin resistance were not significantly different between the groups. The body mass index, fasting plasma glucose, 2 h postprandial plasma glucose, glycosylated hemoglobin test (A1c) and homeostasis model assessment of beta cell function were significantly lower in the glargine group than the liraglutide group (p<0.05). The hypoglycemia rate was lower in the liraglutide group than the glargine group (p<0.05). The Karnofsky performance status score was increased (p<0.05) and the rehospitalization rate and average hospitalization days (p<0.05) were decreased in the liraglutide group. Pearson and linear regression analyses indicated that liraglutide treatment was associated with better glucose control, a better homeostasis model assessment of beta cell function, hypoglycemia rate and Karnofsky performance status score and reduced rehospitalization rate and average hospitalization days. Liraglutide treatment significantly improved glucose control, homeostasis model assessment of beta cell function and the hypoglycemia rate and Karnofsky performance status score and reduced the rehospitalization rate and average hospitalization days of type 2 diabetes patients with malignant tumors treated with glucocorticoids."

基金机构：Joint Medical Research Project of Chongqing Science and Technology Bureau and Health Commission [2021msxm311]; Chongqing Science and Technology Bureau and Health Commission of Chinese Medicine Technology Innovation and Application Development Project [2020ZY013540]; Research Institute Performance Incentive and Guidance Project of Chongqing Science and Technology Bureau [cstc2019jxjl30006]; General Project of Graduate Education and Teaching Reform of Chongqing University [cquyjg20329]; Decision Making Consultation and Management Innovation Project of Science and Technology Bureau of Shapingba District [jcd202038]; 2019 Merck Diabetes Research Fund [g-x-2019-056]

基金资助正文：This work was supported by grants from the Joint Medical Research Project of Chongqing Science and Technology Bureau and Health Commission (2021msxm311); Chongqing Science and Technology Bureau and Health Commission of Chinese Medicine Technology Innovation and Application Development Project (2020ZY013540); Research Institute Performance Incentive and Guidance Project of Chongqing Science and Technology Bureau (cstc2019jxjl30006); General Project of Graduate Education and Teaching Reform of Chongqing University (cquyjg20329); Decision Making Consultation and Management Innovation Project of Science and Technology Bureau of Shapingba District (jcd202038); and 2019 Merck Diabetes Research Fund (g-x-2019-056).